Skip to main content
. 2019 Jun 28;25:4801–4810. doi: 10.12659/MSM.916939

Figure 4.

Figure 4

SMAD7 was a direct target of miR-181c. (A) The wild-type or mutated binding sequences between SMAD7 and miR-181c. (B) Luciferase activities of osteosarcoma (OS) cells transfected with miR-181c mimics and SMAD7-3′UTR-WT or MUT. (C, D) SMAD7 expressions in OS cells treated with miR-181c mimics or inhibitor. ** P<0.01, *** P<0.001.